3 Trending Stocks to Watch, According to Analysts – 8/13/2026
I'm LongbridgeAI, I can summarize articles.Analysts highlight three trending stocks: CoreWeave (CRWV), CAVA Group (CAVA), and BridgeBio Pharma (BBIO). CRWV, a cloud infrastructure firm, received a Moderate Buy consensus with 27.64% upside potential following strong Q2 revenue. CAVA, a restaurant chain, earned a Strong Buy rating with 25.59% upside after beating earnings estimates. BridgeBio Pharma also holds a Strong Buy consensus with 33.68% upside despite mixed Q2 results. All three saw increased analyst ratings in the past 72 hours.
With markets continuing to be volatile, some stocks are drawing attention for their solid fundamentals and rising analyst confidence. TipRanks' Trending Stocks tool allows users to filter activity over the past 30 days, seven days, or even the last 72 hours to see which stocks are drawing the most attention. Checking this page regularly can help you stay ahead of the latest market movers.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Here are the top three most‑rated stocks over the past 72 hours (listed in descending order). Click any ticker to explore all of TipRanks' unique datasets for that stock.
CoreWeave (CRWV) – This cloud infrastructure company specializes in AI computing, providing high-performance GPUs and scalable data center capacity for training and running advanced AI models. CRWV stock has been rated by 19 analysts in the past three days. This flood of ratings came after the company reported strong Q2 revenue growth.
The analyst consensus on the stock is a Moderate Buy. With an average price target of $135.67, the stock has an implied upside potential of 27.64%.
CAVA Group (CAVA) – This fast-growing Mediterranean restaurant chain is known for customizable bowls, pitas, and dips, with a focus on fresh, health-conscious food. The stock is also trending, having been rated 17 times in the past 72 hours. The company is in focus after surpassing Q2 earnings and revenue estimates.
The analyst consensus on the stock is a Strong Buy, with an average price target of $90.65, suggesting an upside potential of 25.59%.
BridgeBio Pharma (BBIO) – This biopharmaceutical company develops therapies for genetically driven diseases. The stock has received 14 ratings over the past 72 hours after delivering mixed Q2 results.
It earned an analyst consensus of Strong Buy and carries an average price target of $108.56, indicating a 33.68% upside potential.